Virtualization of R&D – How should IT and Service Vendors Respond? Neil de Crescenzo, SVP and GM, Oracle Health Sciences Presentation for The PRISME Forum.

Similar presentations

Presentation on theme: "Virtualization of R&D – How should IT and Service Vendors Respond? Neil de Crescenzo, SVP and GM, Oracle Health Sciences Presentation for The PRISME Forum."— Presentation transcript:

2
Virtualization of R&D – How should IT and Service Vendors Respond? Neil de Crescenzo, SVP and GM, Oracle Health Sciences Presentation for The PRISME Forum Special Interest Group October 17, 2011

3
The following is intended to outline our general product direction. It is intended for information purposes only, and may not be incorporated into any contract. It is not a commitment to deliver any material, code, or functionality, and should not be relied upon in making purchasing decisions. The development, release, and timing of any features or functionality described for Oracle’s products remains at the sole discretion of Oracle. Safe Harbor Statement 3

4
Oracle co-wrote a thought leadership series on life sciences trends in 2009 http://www.touchbriefings.com/ebooks/A1p3ok/oracle-virtual/resources/ 4

9
Cloud computing supports flexibility and cross- organizational collaboration Cloud computing spending to increase from $41 billion in 2011 to $241 billion in 2020 (Forrester Research) Growth now fueled by outsourcing business services as much as outsourced IT services Moving from data exchange to integrated business processes and workflows Businesses within an ecosystem collaborate as if organizational boundaries did not exist “Cloud computing represents the dawn of the extensible enterprise.” PriceWaterhouseCoopers Source: PriceWaterhouse Coopers 9

10
Public clouds enable people, applications, and data to collaborate and develop insights BioPharma Diagnostics Medical Devices Healthcare Payers Healthcare Providers Government Payers Regulatory Agencies Patients & Families Provision Your Service. Set up a profile, get an Oracle SSO account, and configure service details. Get a Subscription. Predictable pricing, fixed monthly rates, no term obligation, and no hidden fees. Add Users. Add administrators, developers, and end users. Enrich with Content and Packaged Tools. Add third party content and packaged productivity apps. Operate. Scale, monitor, configure, upgrade, or diagnose. Use our tools or your own. Flex-Deploy. Use a hybrid lifecycle. Your end users and code can deploy on premise or in our cloud. 10 Source: http://cloud.oracle.com/mycloud/f?p=service:how_it_works:0 Open, standards based, flexible platforms that connect domain experts, data and applications in a regulatory-compliant framework

11
Mobile technologies and apps used “at home” are often replacing “company-approved” approaches 11 “…IT departments often greatly underestimate how much employees are using their own technology, including social networks and other web services, for work.” – The Economist, October 8, 2011

12
The “Internet of Things” is far more disruptive than just mobile communications (or the iPad) GSMA estimates 24 billion connected devices in 2020 Discovery and insights will increasingly be fuelled by “thing-generated” data Proteus ingestible event markers (IEMs) are tiny, digestible sensors made from food ingredients. The IEM creates an ultra-low-power, private, digital signal detected by a microelectronic recorder configured as a small bandage style skin-patch. The detector date- and time-stamps, decodes, and records information such as type of drug, dose, and place of manufacture, and also measures and reports physiologic parameters such as heart rate, activity, and respiratory rate. Detector data can be combined at the server level with other telemetered parameters such as blood pressure, weight, blood glucose, and patient-generated feedback. Sources: McKinsey Quarterly, https://www.mckinseyquarterly.com/The_Internet_of_Things_2538;https://www.mckinseyquarterly.com/The_Internet_of_Things_2538 Proteus Biomedical website: http://www.proteusbiomed.com/technology/ 12

13
13 Social networks and the ubiquity of mobile communications create a new usage paradigm

14
Social networks will be built for professionals and institutions but connected to outside networks CTMS, EDC, EHA, Safety, LSH/CDC/LSW, TRC, IRT, OLX, LabPas, CDA Business Insights 14

18
18 Four data pools exist in health sciences that can be leveraged within a common data mgt infrastructure

19
19 A data mgt infrastructure across the health sciences ecosystem captures the majority of the ROI

20
Analytics will move from “reporting” to auto- generating insights – even for protocols… 20 “History flow” visualizes the evolution of a document through time and the contribution of multiple authors. Time appears on the horizontal axis, while contributions are on the vertical axis; each author has a different color code and the vertical length off a bar indicates the amount of text written by each author. Source: McKinsey Institute and Fernanda B. Viegas, Martin Wattenberg, and Kushal Dave, Studying cooperation and conflict between authors with history flow visualizations, CHI2004 proceedings of the SIGCHI conference on human factors in computing systems, 2004.

21
Communities can add value for professionals in health sciences and increasingly patients and families Brings together experts in oncology, information technology, computational biology, pharmaceutical drug development, and personalized medicine Captures, organizes, analyzes, integrates and presents most up-to-date medical facts from a vast array of sources Currently has a 10,000 oncologist, collaborative network Helps enables community physicians to practice more precise medicine for complex conditions Provides members with knowledge needed to treat patients with the more accurate, individualized medicine Goal is to provide “Knowledge Medicine” for cancer care 21 PharmaWall is a fully moderated application that allows companies to engage with Facebook® users in a regulatory-friendly social setting.

30
The two groups are further stratified based on medication 30 Insight

31
Actionable insight: patients in group 2 do not respond well to Dexomethasone Save unnecessary expense by not treating these patients with therapy that is likely to not benefit them Increase quality of life by sparing them unwanted side effects of likely ineffective therapies Enroll these patients in any available new investigational drug trials based on their tumor genetic profile Save unnecessary expense by not treating these patients with therapy that is likely to not benefit them Increase quality of life by sparing them unwanted side effects of likely ineffective therapies Enroll these patients in any available new investigational drug trials based on their tumor genetic profile 31